JP2018520195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520195A5 JP2018520195A5 JP2018502355A JP2018502355A JP2018520195A5 JP 2018520195 A5 JP2018520195 A5 JP 2018520195A5 JP 2018502355 A JP2018502355 A JP 2018502355A JP 2018502355 A JP2018502355 A JP 2018502355A JP 2018520195 A5 JP2018520195 A5 JP 2018520195A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- alkyl
- halo
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 144
- 125000000217 alkyl group Chemical group 0.000 claims description 56
- 125000005843 halogen group Chemical group 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 38
- -1 cyano, amino Chemical group 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 30
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 28
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 28
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 28
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 28
- 125000002837 carbocyclic group Chemical group 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 20
- 102200124918 NRAS G12C Human genes 0.000 claims description 16
- 230000035772 mutation Effects 0.000 claims description 16
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 102100009283 HRAS Human genes 0.000 claims description 14
- 101710033925 HRAS Proteins 0.000 claims description 14
- 102100009279 KRAS Human genes 0.000 claims description 14
- 101710033922 KRAS Proteins 0.000 claims description 14
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 14
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 14
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 10
- 239000000203 mixture Chemical group 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 102200006538 KRAS G12C Human genes 0.000 claims description 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 235000018102 proteins Nutrition 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 102200006614 HRAS G12C Human genes 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 4
- 201000011231 colorectal cancer Diseases 0.000 claims description 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 230000001404 mediated Effects 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 235000002407 Jessenia polycarpa Nutrition 0.000 claims description 2
- 244000232488 Jessenia polycarpa Species 0.000 claims description 2
- 206010027476 Metastasis Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000001769 aryl amino group Chemical group 0.000 claims description 2
- 125000005418 aryl aryl group Chemical group 0.000 claims description 2
- 230000003833 cell viability Effects 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 2
- 125000004468 heterocyclylthio group Chemical group 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 230000000051 modifying Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229940002612 prodrugs Drugs 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 102100001119 NRAS Human genes 0.000 claims 2
- 101710033916 NRAS Proteins 0.000 claims 2
- 230000002489 hematologic Effects 0.000 claims 2
- 206010056981 Adenomatous polyposis coli Diseases 0.000 claims 1
- 0 CC(C(C)=*)C(C(*)=N[C@@]1C=C(C)*)=C(**)[C@]1C=IC=CC Chemical compound CC(C(C)=*)C(C(*)=N[C@@]1C=C(C)*)=C(**)[C@]1C=IC=CC 0.000 description 6
- 201000005787 hematologic cancer Diseases 0.000 description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N Amino radical Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195636P | 2015-07-22 | 2015-07-22 | |
| US62/195,636 | 2015-07-22 | ||
| US201662342078P | 2016-05-26 | 2016-05-26 | |
| US62/342,078 | 2016-05-26 | ||
| GC201631750 | 2016-07-21 | ||
| JO150/2016 | 2016-07-21 | ||
| JOP/2016/0150A JOP20160150B1 (ar) | 2015-07-22 | 2016-07-21 | مركبات كينازولين مستبدلة وطرق استعمالها |
| GCGC-2016-31750 | 2016-07-21 | ||
| PCT/US2016/043568 WO2017015562A1 (fr) | 2015-07-22 | 2016-07-22 | Composés de quinazoline substitués et leur utilisation en tant qu'inhibiteurs de protéines kras, hras et/ou nras mutantes g12c |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520195A JP2018520195A (ja) | 2018-07-26 |
| JP2018520195A5 true JP2018520195A5 (fr) | 2019-08-15 |
| JP6869947B2 JP6869947B2 (ja) | 2021-05-12 |
Family
ID=57821530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502355A Active JP6869947B2 (ja) | 2015-07-22 | 2016-07-22 | 置換キナゾリン化合物ならびにそのｇ１２ｃ変異ｋｒａｓ、ｈｒａｓおよび／またはｎｒａｓタンパク質の阻害剤としての使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3325447A1 (fr) |
| JP (1) | JP6869947B2 (fr) |
| CA (1) | CA2993013A1 (fr) |
| MX (1) | MX2018000777A (fr) |
| WO (1) | WO2017015562A1 (fr) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049568A1 (fr) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Méthodes et compositions permettant l'inhibition de la ras |
| US10246424B2 (en) | 2015-04-10 | 2019-04-02 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| EP3356349A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356359B1 (fr) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3364977A4 (fr) | 2015-10-19 | 2019-09-04 | Araxes Pharma LLC | Méthode de criblage d'inhibiteurs de ras |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| BR112018012914B1 (pt) | 2015-12-22 | 2023-04-18 | SHY Therapeutics LLC | Composto, uso de um composto e composição farmacêutica |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3519402A1 (fr) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| JOP20190154B1 (ar) | 2016-12-22 | 2022-09-15 | Amgen Inc | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| CA3063440A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Inhibiteurs covalents de kras |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| IL271230B1 (en) | 2017-06-21 | 2024-02-01 | SHY Therapeutics LLC | Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases |
| ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
| CN111201237A (zh) * | 2017-09-20 | 2020-05-26 | 美国卫生和人力服务部 | 针对突变的ras的hla ii类限制性t细胞受体 |
| TW201938561A (zh) * | 2017-12-08 | 2019-10-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| TW201942115A (zh) * | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
| MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019217307A1 (fr) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Inhibiteurs de kras g12c |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| MX2020011907A (es) | 2018-05-10 | 2021-01-29 | Amgen Inc | Inhibidores de kras g12c para el tratamiento de cancer. |
| CA3098885A1 (fr) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| BR112020026637A2 (pt) * | 2018-06-27 | 2021-03-30 | Reborna Biosciences, Inc. | Agente profilático ou terapêutico para atrofia muscular espinhal |
| CA3113233A1 (fr) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Derives d'anneaux tricycliques fusionnes utilises en tant qu'inhibiteurs de la phosphatase src a homologie-2 |
| JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CA3117222A1 (fr) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
| EP3924053A1 (fr) | 2019-02-12 | 2021-12-22 | Novartis AG | Combinaison pharmaceutique comprenant tno155 et un inhibiteur de krasg12c |
| JP7426398B2 (ja) | 2019-02-26 | 2024-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒａｓ阻害剤としての新規イソインドリノン置換インドールおよび誘導体 |
| EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
| WO2020234103A1 (fr) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs de kras |
| CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
| EP4051678A1 (fr) | 2019-10-28 | 2022-09-07 | Merck Sharp & Dohme Corp. | Inhibiteurs à petites molécules de mutant de kras g12c |
| TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
| BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
| JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| TW202210633A (zh) | 2020-06-05 | 2022-03-16 | 法商昂席歐公司 | 用於治療癌症之dbait分子與kras抑制劑的組合 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| EP4208261A1 (fr) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2 |
| EP4214209A1 (fr) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Dérivés d'indole servant d'inhibiteurs dans le traitement du cancer |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022140246A1 (fr) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Procédés et composés destinés à l'autophagie ciblée |
| EP4267575A1 (fr) | 2020-12-22 | 2023-11-01 | Nikang Therapeutics, Inc. | Composés pour la dégradation de la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie de l'ubiquitine-protéosome |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| EP4334321A1 (fr) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Inhibiteurs de ras |
| WO2022266206A1 (fr) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Conjugués d'inhibiteurs de kras |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| EP4370522A1 (fr) | 2021-07-14 | 2024-05-22 | Nikang Therapeutics, Inc. | Dérivés d'alkylidène en tant qu'inhibiteurs de kras |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
| WO2023152255A1 (fr) | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Pyrimidines fusionnées utilisées en tant qu'inhibiteurs de kras |
| EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
| WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
| WO2023192801A1 (fr) | 2022-03-28 | 2023-10-05 | Nikang Therapeutics, Inc. | Dérivés sulfonamido utilisés comme inhibiteurs de la kinase 2 dépendant de la cycline |
| WO2023199180A1 (fr) | 2022-04-11 | 2023-10-19 | Novartis Ag | Utilisations thérapeutiques d'un inhibiteur de krasg12c |
| WO2023240024A1 (fr) | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Dérivés de sulfamide utilisés en tant qu'inhibiteurs de kinase 2 dépendant de la cycline |
| WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
| GB202212641D0 (en) | 2022-08-31 | 2022-10-12 | Jazz Pharmaceuticals Ireland Ltd | Novel compounds |
| WO2024102421A2 (fr) | 2022-11-09 | 2024-05-16 | Revolution Medicines, Inc. | Composés, complexes, et leurs procédés de préparation et d'utilisation |
| WO2024102849A1 (fr) | 2022-11-11 | 2024-05-16 | Nikang Therapeutics, Inc. | Composés bifonctionnels contenant des dérivés de pyrimidine 2,5-substitués pour dégrader la kinase 2 dépendante des cyclines par l'intermédiaire d'une voie ubiquitine-protéasome |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI271406B (en) * | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| JP2002371078A (ja) * | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | キノリン誘導体及びキノロン誘導体 |
| AU2002352444A1 (en) * | 2001-12-20 | 2003-07-09 | Celltech R And D Limited | Quinazolinedione derivatives |
| EP1723146A1 (fr) * | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Derives de pyrazole fondu en tant qu'inhibiteurs de transduction de signal tgf-beta pour traiter les fibroses et les neoplasmes |
| TW200643015A (en) * | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AU2011282588B2 (en) * | 2010-07-30 | 2016-01-07 | Oncotherapy Science, Inc. | Quinoline derivatives and MELK inhibitors containing the same |
| BR112015022417A2 (pt) * | 2013-03-14 | 2017-07-18 | Convergene Llc | métodos e composições para inibição de proteínas contendo bromodomínio |
| UA119971C2 (uk) * | 2013-10-10 | 2019-09-10 | Араксіс Фарма Ллк | Інгібітори g12c kras |
| NZ724691A (en) * | 2014-03-24 | 2018-02-23 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
-
2016
- 2016-07-22 JP JP2018502355A patent/JP6869947B2/ja active Active
- 2016-07-22 WO PCT/US2016/043568 patent/WO2017015562A1/fr active Application Filing
- 2016-07-22 EP EP16747678.7A patent/EP3325447A1/fr not_active Withdrawn
- 2016-07-22 MX MX2018000777A patent/MX2018000777A/es unknown
- 2016-07-22 CA CA2993013A patent/CA2993013A1/fr not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520195A5 (fr) | ||
| JP2017528498A5 (fr) | ||
| JP2018511631A5 (fr) | ||
| JP2018533611A5 (fr) | ||
| JP2020505395A5 (fr) | ||
| JP2019534260A5 (fr) | ||
| JP2020505396A5 (fr) | ||
| JP2020521741A5 (fr) | ||
| JP2017508789A5 (fr) | ||
| JP2014503567A5 (fr) | ||
| RU2016118753A (ru) | Производные пиридилкетона, способ их получения и их фармацевтическое применение | |
| RU2005122901A (ru) | Производные пиридино [2,3-] пиримидина в качестве селективных ингибиторов kdr и fgfr | |
| JP2013513613A5 (fr) | ||
| JP2013512903A5 (fr) | ||
| RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
| RU2013128448A (ru) | Производные триазола в качестве ингибиторов сигнального пути wnt | |
| JP2016519072A5 (fr) | ||
| JP2015522650A5 (fr) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| RU2013106754A (ru) | Производное фталазинонкетона, способ его получения и его фармацевтическое применение | |
| JP2001526222A5 (fr) | ||
| RU2015106434A (ru) | Производные типа азаиндазола или диазаиндазола для лечения боли | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2014506599A5 (fr) | ||
| JP2015520143A5 (fr) |